Taisho Pharmaceutical Holdings Co Ltd (Pre-Merger)
Taisho Pharmaceutical's GHG Emissions Data Preview
In 2021, Taisho Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
Taisho Pharmaceutical has also provided a category-level breakdown for 8 out of 15 Scope 3 emissions categories, offering greater transparency into its value chain emissions.
| Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
|---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data.  | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
Insights into Taisho Pharmaceutical's Operational Emissions
In 2021, the total operational greenhouse gas (GHG) emissions of Taisho Pharmaceutical amounted to 50,085 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2020, the total operational greenhouse gas (GHG) emissions of Taisho Pharmaceutical decreased by 3.47%, showing that the company has made progress in taking action to reduce the climate impact of its operations.
Taisho Pharmaceutical's Scope 1 Emissions Over Time
- Total Scope 1
- Year-over-Year Change
What are Taisho Pharmaceutical's Scope 1 emissions?
In 2021, the total Scope 1 emissions of Taisho Pharmaceutical were 22,353 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Has Taisho Pharmaceutical reduced its Scope 1 emissions over time?
Since 2018, Taisho Pharmaceutical's Scope 1 emissions have decreased by 13.72%, reflecting a declining long-term trend in Scope 1 emissions over time.
Compared to the previous year (2020), Taisho Pharmaceutical's Scope 1 emissions decreased by 2.59%, highlighting the company's efforts to lower direct emissions from assets it owns or controls.
What are Taisho Pharmaceutical's Scope 2 emissions?
In 2021, Taisho Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 27,732 tCOâ‚‚e without specifying the calculation method.
Has Taisho Pharmaceutical reduced its Scope 2 emissions over time?
Since 2018, Taisho Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have decreased by 15.49%, reflecting a declining long-term trend in Scope 2 emissions over time.
Compared to the previous year (2020), Taisho Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) have remained relatively stable, indicating that Taisho Pharmaceutical 's emissions have plateaued with no significant change in its energy consumption footprint.
What methodology does Taisho Pharmaceutical use for Scope 2 reporting?
In 2021, Taisho Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.
Taisho Pharmaceutical's Scope 2 Emissions Over Time
- Total Scope 2 (Unspecified Calculation Method)
Insights into Taisho Pharmaceutical's Value Chain Emissions
In 2021, Taisho Pharmaceutical reported 145,850 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2021 disclosure of Taisho Pharmaceutical includes a breakdown across 8 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2020, demonstrating consistent Scope 3 emissions reporting coverage year over year.
Taisho Pharmaceutical's Scope 3 Emissions Over Time
- Total Scope 3
- Year-over-Year Change
What are Taisho Pharmaceutical's Scope 3 emissions?
In 2021, Taisho Pharmaceutical reported total Scope 3 emissions of 145,850 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Approximately 99.38% of these emissions originated from upstream activities such as purchased goods and capital goods, while 0.62% came from downstream activities like product use, distribution, and end-of-life treatment.
Compared to the previous year (2020), Taisho Pharmaceutical's Scope 3 emissions remained relatively stable, indicating that Taisho Pharmaceutical 's emissions have plateaued with no significant change in its value chain footprint.
What categories of Scope 3 emissions does Taisho Pharmaceutical disclose?
In 2021, Taisho Pharmaceutical reported emissions for 8 out of the 15 Scope 3 categories defined by the GHG Protocol.
This partial disclosure allows for some insight into the company's indirect impacts.
What are the main sources of Taisho Pharmaceutical's Scope 3 emissions?
In 2021, the largest contributors to Taisho Pharmaceutical's Scope 3 emissions were:
- Purchased Goods and Services (Cat. 1): 81,264 tCOâ‚‚e (55.72%)
- Capital Goods (Cat. 2): 47,764 tCOâ‚‚e (32.75%)
- Upstream Transportation and Distribution (Cat. 4): 7,954 tCOâ‚‚e (5.45%)
Taisho Pharmaceutical's Scope 3 Emissions by Categories
Insights into Taisho Pharmaceutical's Total Carbon Footprint
In 2021, Taisho Pharmaceutical reported a total carbon footprint of 195,935 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 2.3% decrease compared to 2020, indicating progress in reducing its overall greenhouse gas output.
The largest contributor to Taisho Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 74.44% of the company's total carbon footprint, followed by Scope 2 emissions at 14.15%.